Negative Diffusion-Weighted Imaging After Intravenous Tissue-Type Plasminogen Activator is Rare and Unlikely to Indicate Averted Infarction
Stroke 44-1629-1634, Freeman, J.,et al, 2013
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
What is Meant by "TICI"?
AJNR 34:1792-1797, Fugate,J.E.,et al, 2013
Solitaire Flow Restoration Device Versus the Merci Retriever in Patients with Acute Ischaemic Stroke (SWIFT): a Randomised, Parallel-Group, Non-Inferiority Trial
Lancet 380:1241-1249,1208, Saver, J.L.,et al, 2012
Trevo Versus Merci Retrievers for Thrombectomy Revascularisation of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2): A Randomised Trial
Lancet 380:1231-1240,1208, Nogueira, R.G.,et al, 2012
Chronic Pain as a Manifestation of Potassium Channel-Complex Autoimmunity
Neurol 79:1136-1144, Klein, C.J.,et al, 2012
Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated with Recombinant Tissue Plasminogen Activator
Stroke 43:2904-2909, Whiteley, W.N.,et al, 2012
Time is Brain(stem) in Basilar Artery Occlusion
Stroke 43:3003-3006, Vergouwen, M.D.I.,et al, 2012
Smartphone Teleradiology Application is Succesfully Incorporated Into a Telestroke Network Environment
Stroke 43:3098-3101, Demaerschalk, B.M.,et al, 2012
Fluid-Attenuated Inversion Recovery Vascular Hyperintensity
Arch Neurol 69:1462-1468, Olindo, S.,et al, 2012
The Safety of Intravenous Thrombolysis for Ischemic Stroke in Patients with Pre-Existing Cerebral Aneurysms
Stroke 43:412-416, Edwards,N.J.,et al, 2012
The Argatroban and Tissue-Type Plasminogen Activator Stroke Study
Stroke 43:770-775,623, Barreto,A.D.,et al, 2012
Does Helicopter Emergency Medical Service Transfer Offer Benefit to Patients with Stroke?
Stroke 43:878-880, Olson,M.D. and Rabinstein,A.A., 2012
The Types of Neurological Deficits Might Not Justify Withholding Treatment in Patients with Low Total National Institutes of Health Stroke Scale Scores
Stroke 43:782-786,625, Leira,E.C.,et al, 2012
Selecting Stroke Patients for Intra-Arterial Therapy
Neurol 78:755-761, Balucani,C. and Grotta,J.C., 2012
Safety of Thrombolysis in Patients Over the Age of 80
The Neuroogist 18:99-101, Willey,J.Z.,et al, 2012
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
NEJM 366:1099-1107, Parsons,M.,et al, 2012
Infarct Volume is a Pivotal Biomarker After Inter-Arterial Stroke Therapy
Stroke 43:1323-1330, Yoo,A.J.,et al, 2012
Bridging Therapy in Acute Ischemic Stroke
Stroke 43:1302-1308, Mazighi,M.,et al, 2012
Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis: The SEDAN Score
Ann Neurol 71:634-641, Strbian,D.,et al, 2012
Central Nervous System Neuronal Surface Antibody Associated Syndromes: Review and Guidelines for Recognition
JNNP 83:638-645, Zuliani,L.,et al, 2012
Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012
Acute Stroke Imaging: What is Sufficient for Triage to Endovascular Therapies?
AJNR 33:790-792, Lev, M.H., 2012
Factors Influencing In-Hospital Delay in Treatment with Intravenous Thrombolysis
Stroke 43:1578-1583, Mikulik, R.,et al, 2012
The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the third international stroke trial IST-3): a Randomised Controlled Trial
Lancet 379: 2320, IST-3 collaborative group, 2012
Recombinant Tissue Plasminogen Activator for Acute Ischaemic Stroke: An Updated Systematic Review and Meta-Analysis
Lancet 379: 2364-2372, Wardlaw, J.M.,et al, 2012
Treatment of ?-Aminobutyric Acid� Receptor-Antibody Autoimmune Encephalitis with Oral Corticosteroids
Arch Neurol 69:1061-1063, Goldenholz, D.M.,et al, 2012
Early Administration of Aspirin in Patients Treated with Alteplase for Acute Ischaemic Stroke: A Randomised Controlled Trial
Lancet 380:731-737, Zinkstok, S.M.,et al, 2012
Elderly Patients are at Higher Risk for Poor Outcomes after Intra-Arterial Therapy
Stroke 43:2356-2361, Chandra, R.V.,et al, 2012
A Pragmatic Approach Using Magnetic Resonance Imaging to Treat Ischemic Strokes of Unknown Onset Time in a Thrombolytic Trial
Stroke 43:2331-2335, Song, S.S.,et al, 2012
Intravenous Thrombolysis in Nonagenarians With Ischemic Stroke
Stroke 42:1967-1970, Sarikaya, H.,et al, 2011
Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age
JNNP 82:712-717, Bhatnagar, P.,et al, 2011
Encephalitis and antibodies to synaptic and neuronal cell surface proteins
Neurol 77:179-189, Lancaster, E.,et al, 2011
Subtherapeutic International Normalized Ratio in Warfarin-Treated Patients Increases the Risk for Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis
Stroke 42:2333-2335, Seet, R.C.S.,et al, 2011
Impact of Obesity on Stroke Outcome After Intravenous Thrombolysis
Stroke 42:2330-2332, Sarikaya, H.,et al, 2011
Efficacy of Intravenous Tissue-Type Plasminogen Activator in Central Retinal Artery Occlusion Report From a Randomized, Controlled Trial
Stroke 42:2229-2234, Chen, C.S.,et al, 2011
Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis
Neurol 77:341-348, Strbian, D.,et al, 2011
Advanced Brain Imaging Studies Should Be Performed in Patients With Suspected Stroke Presenting Within 4.5 Hours of Symptom Onset
Stroke 42-2666-2667,2670, Parsons, M.W., 2011
Advanced Brain Imaging Studies Should Not Be Performed in Patients With Suspected Stroke Presenting Within 4.5 Hours of Symptom Onset
Stroke 42:2668-2669,2670, Lyden, P.D., 2011
Safety and Functional Outcome of Thrombolysis in Dissection-Related Ischemic Stroke A Meta-Analysis of Individual Patient Data
Stroke 42:2515-2520, Zinkstok, S.M.,et al, 2011
Effects of Extending the Time Window of Thrombolysis to 4.5 Hours Observations in the Swedish Stroke Register (Riks-Stroke)
Stroke 42:2492-2497, Asplund, K.,et al, 2011
Autoimmune encephalitis
BMJ 342:d1918, Irani, S.R.,et all, 2011
Helicopter Transport of Stroke Patients and Its Influence on Thrombolysis Rates
Stroke 42:1295-1300, Reiner-Deitemyer, V.,et al, 2011
Prevalence of MRI-defined recent silent ischemia and associated bleeding risk with thrombolysis
Neurol 76:1288-1295, Tisserand, M.,et al, 2011
Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase
BMJ 342:d1938, McArthur, K.S.,et al, 2011
VGKC antibodies in pediatric encephalitis presenting with status epilepticus
Neurology 76:1252-1255, Suleiman, J.,et al, 2011
Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine
Neurol 76:1780-1781, Tong, D., 2011
Safety and Outcomes of Intravenous Thrombolysis in Stroke Mimics
Stroke 42:1771-1774, Tsivgoulis, G.,et al, 2011
Reliability of Prehospital Real-Time Cellular Video Phone in Assessing the Simplified National Institutes of Health Stroke Scale in Patients With Acute Stroke
Stroke 42:1522-1527, Gonzalez, M.A.,et al, 2011
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
NEJM 364:22, Wechsler, L.R., 2011